PATIENTSUPPORT

Patient support through Alnylam Assist®

The Alnylam Assist® resources on this page are here to help your patients with
primary hyperoxaluria type 1 (PH1).
 

Image
Alnylam Assist® Logo

Here to help your patients 

Alnylam Assist® offers personalized support for patients being treated with OXLUMO™ (lumasiran). If you would like to access OXLUMO for one of your patients, the first step is completing the Start Form.

Image
'

Electronic Start Form

Fill out the Electronic Start Form online with your patient.

Get Started

Image
'

Downloadable Start Form

Print the Start Form, complete it with your patient, then fax it to 1-833-256-2747. 

Download

Image
'

DocuSign Start Form

Begin the Start Form, then send it to your patient via email to complete their portion.

Begin Start Form

See DocuSign Instructions

What happens next?

  1. A Case Manager will reach out to either you or your patient within 1-2 business days of receiving the completed Start Form.
  2. The Alnylam Assist® team will help your patient access OXLUMO.
Image
`

Alnylam Assist® offers comprehensive support for your patients throughout the treatment journey:

Image
'

Benefits verification Help determining patient-specific coverage. Within 1-2 days, a summary of benefits will be communicated to you and your patient

Image
'

Financial assistance Information about patient eligibility for financial assistance, such as our Commercial Copay Program, Patient Assistance Program for uninsured patients, and more*

Image

Patient educationDisease education and product information for patients and their families through trained Patient Education Liaisons (PELs)

Image

Reimbursement educationAn Alnylam Field Reimbursement Director is available to provide education about billing, coding, and the reimbursement process for OXLUMO to physicians and their office staff.

Tell Me More About Alnylam Assist®

 

Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

OXLUMO™ (lumasiran) Patient Brochure Preview

Downloadable patient brochure

A guide to help your patients better understand their condition and navigate treatment with OXLUMO.

OXLUMO™ (lumasiran) Patient Brochure PreviewDownload the OXLUMO patient brochure for more information.

Download

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Patient advocacy organizations

Help your patient expand their network and stay informed by connecting them with independent patient advocacy organizations.

Image
Oxalosis and Hyperoxaluria Foundation Logo

Visit Site

Image
American Kidney Fund Logo

Visit Site

Image
National Kidney Foundation Logo

Visit Site

We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with any of these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace a doctor’s medical advice.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO™ (lumasiran) was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.